BSE · 511509
Vivo Bio Tech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹0 Cr — a 1.27% net margin, versus -39.51% the period before.
Shareholding
As of 2026-06-30
- Promoter30.62%
- Public69.38%
21,224 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.36× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 4.81 percentage points to 30.62% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #77 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Vivo Bio Tech Ltd.(this company) | ₹46 Cr | — | 0.51 | -1.83% | -5.17% |
AI analysis
AI-generated · google/gemini-2.5-flashVivo Bio Tech Ltd. is listed on the Indian markets with a market capitalization of Rs 53 Cr. The company reported a revenue of Rs 51.48 Cr and a negative profit margin of -5.17%. Its 52-week high was Rs 43.35 and the 52-week low was Rs 20.35. As of June 30, 2026, promoter holding was 30.6188% with public shareholding at 69.3812%.
Positives
- +The 52-week high of Rs 43.35 indicates previous investor confidence.
- +The company's market capitalization of Rs 53 Cr suggests it is a small-cap company.
- +Promoter pledge is 0%, indicating no shares are pledged.
Negatives
- −The company has a negative profit margin of -5.17%.
- −Return on equity (ROE) is significantly negative at -183.4%.
- −Earnings per share (EPS) is 0.
- −The debt-to-equity ratio is 0.96.
- −The public shareholding of 69.3812% is higher than the promoter holding of 30.6188% as of June 30, 2026.
Financial Performance
For the quarter ending June 2026, Vivo Bio Tech Ltd. reported revenue of Rs 14.28 Cr and a net profit of Rs 0.19 Cr. In the preceding quarter ending March 2026, revenue stood at Rs 14.2 Cr with a net profit of -Rs 5.16 Cr. This follows a revenue of Rs 13.51 Cr and net profit of Rs 1.25 Cr in December 2025.
Profitability & Returns
The company recorded a negative return on equity (ROE) of -183.4%. Return on Capital Employed (ROCE) was 6.6394%. The profit margin was -5.17% on a revenue of Rs 51.48 Cr, indicating losses relative to sales. Earnings per share (EPS) is 0.
Balance Sheet
Vivo Bio Tech Ltd. has a debt-to-equity ratio of 0.96. The book value per share is Rs 41.25. The company has not provided a dividend yield.
Ownership & Pledges
As of June 30, 2026, promoter holding in Vivo Bio Tech Ltd. was 30.6188%, while public shareholders held 69.3812% of the company. There were no FII or DII holdings reported. The number of shareholders was 21,224. There are no reported promoter pledges.
Data as of — price: 2026-07-29 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.